Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.
Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.
Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Kevin Grogan
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
Promising data from the likes of Provention Bio and Diamyd Medical suggest that treatment for the autoimmune disorder type 1 diabetes could soon move beyond insulin.
The Italian firm has laid out its ambitious plan to introduce the first carbon minimal pressurized metered dose inhaler for asthma and COPD by 2025 and secured supply of a new environmentally friendly propellant.